Monitoring gonadotropin-releasing hormone administration by measurement of urinary steroid conjugates

Obstet Gynecol. 1986 May;67(5):710-7. doi: 10.1097/00006250-198605000-00020.

Abstract

The use of measuring urinary steroid conjugates in nontimed, randomly collected morning urine samples expressed as a function of creatinine concentration was assessed to monitor ovarian response to pulsatile administration of gonadotropin-releasing hormone in ambulatory patients. This method of evaluating ovarian steroid production provided a convenient, inexpensive, and noninvasive means of monitoring responses to gonadotropin-releasing hormone treatments and documents that clomiphene-resistant amenorrheic patients can be induced to ovulate with appropriate gonadotropin-releasing hormone therapy. Different ovarian responses in the same woman to similar doses and frequencies of gonadotropin-releasing hormone indicate that discrete adjustments of individual doses may be required to facilitate consistent ovulatory responses. The strategy presented here allows for subsequent gonadotropin-releasing hormone therapy in the individual patient to be determined by an objective and quantifiable ovarian response to an initial treatment.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Amenorrhea / drug therapy
  • Creatinine / urine
  • Estrogens / urine
  • Female
  • Humans
  • Infertility, Female / drug therapy*
  • Infertility, Female / metabolism
  • Menstrual Cycle
  • Ovulation / drug effects
  • Pituitary Hormone-Releasing Hormones / administration & dosage*
  • Pituitary Hormone-Releasing Hormones / metabolism
  • Pregnanediol / urine
  • Radioimmunoassay
  • Steroids / urine*

Substances

  • Estrogens
  • Pituitary Hormone-Releasing Hormones
  • Steroids
  • Creatinine
  • Pregnanediol